Eli Lilly’s ongoing 24-month SmartDepot evaluation agreement with Peptron, extended through October 2026, keeps the commercial licensing window open for the sustained-release microsphere platform applied to peptide candidates like GLP-1 agonists. Trader sentiment remains balanced at 54% for No because Lilly simultaneously secured rights to Camurus’ competing FluidCrystal technology for up to four incretin therapies in 2025 and has accelerated oral obesity programs, raising doubts about prioritizing injectable depot formulations. Key swing factors include the upcoming completion of the joint research committee’s formulation data, any public statements on technology transfer negotiations, and Lilly’s next regulatory or pipeline updates on long-acting versus oral delivery options that could either confirm or sideline the non-exclusive Peptron license before the deadline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयानया
नया
7 अक्टू, 2026
नया
नया
7 अक्टू, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing 24-month SmartDepot evaluation agreement with Peptron, extended through October 2026, keeps the commercial licensing window open for the sustained-release microsphere platform applied to peptide candidates like GLP-1 agonists. Trader sentiment remains balanced at 54% for No because Lilly simultaneously secured rights to Camurus’ competing FluidCrystal technology for up to four incretin therapies in 2025 and has accelerated oral obesity programs, raising doubts about prioritizing injectable depot formulations. Key swing factors include the upcoming completion of the joint research committee’s formulation data, any public statements on technology transfer negotiations, and Lilly’s next regulatory or pipeline updates on long-acting versus oral delivery options that could either confirm or sideline the non-exclusive Peptron license before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
बाज़ार खुला: May 5, 2026, 8:02 PM ET
वॉल्यूम
$8,217समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing 24-month SmartDepot evaluation agreement with Peptron, extended through October 2026, keeps the commercial licensing window open for the sustained-release microsphere platform applied to peptide candidates like GLP-1 agonists. Trader sentiment remains balanced at 54% for No because Lilly simultaneously secured rights to Camurus’ competing FluidCrystal technology for up to four incretin therapies in 2025 and has accelerated oral obesity programs, raising doubts about prioritizing injectable depot formulations. Key swing factors include the upcoming completion of the joint research committee’s formulation data, any public statements on technology transfer negotiations, and Lilly’s next regulatory or pipeline updates on long-acting versus oral delivery options that could either confirm or sideline the non-exclusive Peptron license before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
वॉल्यूम
$8,217समाप्ति तिथि
7 अक्टू, 2026बाज़ार खुला
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing 24-month SmartDepot evaluation agreement with Peptron, extended through October 2026, keeps the commercial licensing window open for the sustained-release microsphere platform applied to peptide candidates like GLP-1 agonists. Trader sentiment remains balanced at 54% for No because Lilly simultaneously secured rights to Camurus’ competing FluidCrystal technology for up to four incretin therapies in 2025 and has accelerated oral obesity programs, raising doubts about prioritizing injectable depot formulations. Key swing factors include the upcoming completion of the joint research committee’s formulation data, any public statements on technology transfer negotiations, and Lilly’s next regulatory or pipeline updates on long-acting versus oral delivery options that could either confirm or sideline the non-exclusive Peptron license before the deadline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न